Vertex, Inc. (NASDAQ:VERX) reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX ... The shares were purchased at a price of $38.51, marking a strategic addition to Vanguard's diverse investment portfolio.

Analyst Joshua Reilly of Needham maintained a Buy rating on Vertex (VERX – Research Report), boosting the price target to $60.00. Joshua ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The 12-month price targets assessed by analysts reveal further insights ... Stay informed and make strategic decisions with our Ratings Table. Vertex Inc is a provider of tax technology and services.

Vertex's estimated fair value is US$75.54 based on 2 Stage Free Cash Flow to Equity Vertex is estimated to be 43% undervalued based on current share price of ... of Vertex, Inc. (NASDAQ:VERX ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

UK politicians could go public with the price of Vertex's cystic fibrosis drug Orkambi, if the company does not strike a deal giving NHS patients access by the end of the month.

JPMorgan Chase & Co. lifted their price objective on Vertex Pharmaceuticals ... GHP Investment Advisors Inc. acquired a new position in Vertex Pharmaceuticals during the second quarter worth ...

Good day, and welcome to the Vertex Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation ...

KING OF PRUSSIA, Pa. (AP) — KING OF PRUSSIA, Pa. (AP) — Vertex, Inc. (VERX) on Wednesday reported third-quarter profit of $7.2 million. On a per-share basis, the King Of Prussia, Pennsylvania-based ...

Scotiabank’s price target suggests a potential ... Finally, Ipswich Investment Management Co. Inc. increased its stake in Vertex Pharmaceuticals by 2.7% in the 3rd quarter.